The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Nicola Edwards, Richard Steeds, Colin Chue, Paul Stewart, Charles Ferro, Jonathan Townend

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of
Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusPublished - 28 Sep 2011

Fingerprint

Dive into the research topics of 'The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.'. Together they form a unique fingerprint.

Cite this